ARDX is expected to report earnings to fall 76.87% to -3 cents per share on July 30
Q2'26
Est.
$-0.03
Q1'26
Missed
by $0.02
Q4'25
Missed
by $0.02
Q3'25
Beat
by $0.06
Q2'25
Beat
by $0.05
The last earnings report on April 30 showed earnings per share of -15 cents, missing the estimate of -12 cents. With 3.09M shares outstanding, the current market capitalization sits at 1.53B.
A.I. Advisor
published General Information
General Information
a developer of therapeutic drugs that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases
A.I.dvisor indicates that over the last year, ARDX has been loosely correlated with VCYT. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ARDX jumps, then VCYT could also see price increases.
ARDX in +9.07% Uptrend, rising for three consecutive days on June 22, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ARDX advanced for three days, in of 261 cases, the price rose further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ARDX's RSI Indicator exited the oversold zone, of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on June 16, 2026. You may want to consider a long position or call options on ARDX as a result. In of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for ARDX just turned positive on June 16, 2026. Looking at past instances where ARDX's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .
ARDX moved above its 50-day moving average on June 22, 2026 date and that indicates a change from a downward trend to an upward trend.
The 50-day moving average for ARDX moved above the 200-day moving average on May 21, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The 10-day moving average for ARDX crossed bearishly below the 50-day moving average on June 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARDX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ARDX broke above its upper Bollinger Band on June 18, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ARDX entered a downward trend on June 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ARDX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.593) is normal, around the industry mean (20.966). P/E Ratio (0.000) is within average values for comparable stocks, (36.007). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). ARDX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (3.617) is also within normal values, averaging (367.026).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
